Stage Iii Esophageal Cancer: Disease Bioinformatics
Esophageal cancers typically begin in the bottom portion of the esophagus, and affect more men than women. The cancer is typically diagnosed at a late stage, so it has a relatively poor prognosis. There are two types of esophageal cancer: squamous cell carcinoma and adenocarcinoma. Risk factors include: older age, poor diet, drinking alcohol, obesity, gastroesophageal reflux disease, smoking, chewing tobacco, and radiation treatment to the chest or upper abdomen. It is not a very common cancer in the United States, but it has higher incidence rates in places like Asia and Africa. Treatments include surgery, chemotherapy, radiation, and clinical trials. In stage III of esophageal cancer, the cancer has spread to the inner muscle layer of the connective tissue wall, and may have localized beyond the esophagus into nearby or distant organs, tissues, and lymph nodes. Stage III is considered an agressive stage of cancer and is difficult to treat.
Stage Iii Esophageal Cancer Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Stage Iii Esophageal Cancer below!
For more information on how to use Laverne, please read the How to Guide.
We have 1803 products for the study of Stage Iii Esophageal Cancer that can be applied to Western Blot, Immunocytochemistry/Immunofluorescence, Flow Cytometry, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Stage Iii Esophageal Cancer is also known as Esophageal Cancer, Stage Iii.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.